Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL

Jeffrey Lancet • 9 Jun 2020
EHA 2020
Acute Promyelocytic Leukemia Leukemia Rare Diseases All-trans retinoic acid Antibodies Arsenic trioxide Gemtuzumab ozogamicin

Jeffrey Lancet, MD, of H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, reports results from a Phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk acute promyelocytic leukemia (APL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jeffrey Lancet

The role of transfusion support in older patients with AML no longer receiving active therapy
1:39
The role of transfusion support in older patients with AML no longer receiving active therapy
Jeffrey Lancet • 6 May 2026
Post-remission therapy in older adults with newly diagnosed AML and when to consider transplant
2:44
Post-remission therapy in older adults with newly diagnosed AML and when to consider transplant
Jeffrey Lancet • 6 May 2026
Barriers community oncologists may face when implementing ASH guidelines in older patients with AML
2:52
Barriers community oncologists may face when implementing ASH guidelines in older patients with AML
Jeffrey Lancet • 6 May 2026
Deciding whether an older patient with AML is a suitable candidate for antileukemic therapy
2:13
Deciding whether an older patient with AML is a suitable candidate for antileukemic therapy
Jeffrey Lancet • 6 May 2026

Related Videos

Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
1:22
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
Marta Coscia • 16 Oct 2026
Choosing between fixed-duration and continuous BTK inhibitor therapy in newly diagnosed CLL
1:35
Choosing between fixed-duration and continuous BTK inhibitor therapy in newly diagnosed CLL
Marta Coscia • 16 Oct 2026
Novel targets, combinations, and treatments in AML: insights from iwAL 2026
19:38
Novel targets, combinations, and treatments in AML: insights from iwAL 2026
Gail Roboz et al. • 7 Oct 2026
AVC-201: a CAR-T using a switchable module in AML
13:39
AVC-201: a CAR-T using a switchable module in AML
Marion Subklewe • 19 Sep 2026
The content of VJHemOnc is intended for healthcare professionals